Table 1 Patients characteristics
From: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
Characteristic | No. (%) |
|---|---|
Age (mean and range) | 62 (31–77) |
Sex | |
Male | 54 (59%) |
Female | 37 (41%) |
ECOG performance status | |
0 | 50 (55%) |
1 | 39 (43%) |
2 | 2 (2%) |
Primary site | |
Colon | 54 (59%) |
Rectum | 37 (41) |
Metastasis sites | |
Liver | 65 (71%) |
Lung | 29 (32%) |
Local abdominal mass | 23 (25%) |
Others | 22 (24%) |
No. of metastatic sites | |
1 | 34 (37%) |
2 | 25 (28%) |
⩾3 | 32 (35%) |
Adjuvant chemotherapy | |
Yes | 44 (48%) |
No | 47 (52%) |
